{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:15Z","timestamp":1790409255429,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00433-y","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T16:33:11Z","timestamp":1776529991000},"page":"827-839","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases"],"prefix":"10.1007","volume":"14","author":[{"given":"Surbhi","family":"Sidana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh P.","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Lengil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"5","key":"433_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386.","journal-title":"Cancer Gene Ther"},{"key":"433_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"issue":"4","key":"433_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"key":"433_CR4","unstructured":"US Food & Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma. Accessed 9 Jan 2026."},{"issue":"10297","key":"433_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8.","journal-title":"Lancet"},{"key":"433_CR6","unstructured":"CARVYKTI | FDA (U.S. Food and Drug Administration) (2024)."},{"issue":"1","key":"433_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2023000472","volume":"2023","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Locke FL. Recognizing, defining, and managing CAR-T hematologic toxicities. Hematology. 2023;2023(1):198\u2013208.","journal-title":"Hematology"},{"issue":"4","key":"433_CR8","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","volume":"26","author":"CE Graham","year":"2025","unstructured":"Graham CE, Velasco R, Tomas AA, et al. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Oncol. 2025;26(4):e203\u201313.","journal-title":"Lancet Oncol"},{"issue":"1","key":"433_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"issue":"4 (Supplement)","key":"433_CR10","doi-asserted-by":"publisher","first-page":"A6183","DOI":"10.1016\/j.chest.2023.07.3978","volume":"164","author":"D Rutenberg","year":"2023","unstructured":"Rutenberg D. Guillain\u2013Barr\u00e9 syndrome following anti-BCMA CAR-T cell therapy. Chest. 2023;164(4 (Supplement)):A6183\u20134.","journal-title":"Chest"},{"key":"433_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1182\/blood-2025-133","volume":"146","author":"H Mian","year":"2025","unstructured":"Mian H, Faisal MS, Chen T, et al. Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: a CIBMTR analysis. Blood. 2025;146:133.","journal-title":"Blood"},{"key":"433_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01441-3","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Tan M, Parrondo R, et al. Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J. 2025. https:\/\/doi.org\/10.1038\/s41408-025-01441-3.","journal-title":"Blood Cancer J"},{"key":"433_CR13","unstructured":"Janssen Biotech I. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Accessed 9 Jan 2026."},{"issue":"6","key":"433_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676\u201382. https:\/\/doi.org\/10.1093\/aje\/kwq433.","journal-title":"Am J Epidemiol"},{"key":"433_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/CCI.19.00094","volume":"4","author":"BG Patel","year":"2020","unstructured":"Patel BG, Luo S, Wildes TM, Sanfilippo KM. Frailty in older adults with multiple myeloma: a study of US veterans. JCO Clin Cancer Inform. 2020;4:117\u201327. https:\/\/doi.org\/10.1200\/CCI.19.00094.","journal-title":"JCO Clin Cancer Inform"},{"key":"433_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM. Real-world data: bridging the gap between clinical trials and practice. EClinicalMedicine. 2024;78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"433_CR17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-96","volume":"146","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Velayati A, Dima D, et al. Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146(1):96.","journal-title":"Blood"},{"key":"433_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","volume":"96","author":"F Vonberg","year":"2025","unstructured":"Vonberg F, Malik I, O\u2019Reilly M, Hyare H, Carr A, Roddie C. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. J Neurol Neurosurg Psychiatry. 2025;96:665\u201378.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"433_CR19","unstructured":"Driscoll ME, Bollu PC, Tadi P. Neuroanatomy, Nucleus Caudate. Treasure Island (FL): StatPearls Publishing; 2023."},{"issue":"Supplement 1","key":"433_CR20","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2025-2215","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Iida S, Sidiqi MH, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Blood. 2025;146(Supplement 1):2215.","journal-title":"Blood."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00433-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:53:21Z","timestamp":1782381201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00433-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00433-y","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Surbhi Sidana has received consulting fees and\/or served on advisory boards for Takeda, BMS, Johnson & Johnson, Legend Biotech, Sanofi, BiolineRx, Pfizer, Regeneron, AbbVie, Genentech, and Kite\/Arcellx, and has received research funding from BMS, Johnson & Johnson, Kite, and Novartis. Saurabh P. Nagar, Sabyasachi Ghosh, Lin Fan, Victoria Alegria, Kevin C. De Braganca, Tamar Lengil, Mukta Sharma, Helen Pai, Todd Bixby, and Zaina P. Qureshi are employees and stockholders of Johnson & Johnson. Matthew Perciavalle is an employee of Legend Biotech and owns stock\/stock options in Legend Biotech. Jessica Maitland and Bruno Emond are employees of Analysis Group ULC, a consulting company that has provided paid consulting services to Johnson & Johnson. Rafael Fonseca has received royalties for a patent for FISH in MM, has received consulting fees from AbbVie, Adaptive, Amgen, Apple, Bayer, BMS\/Celgene, Gilead, GSK, Johnson & Johnson, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, ArduroBiotech, OncoTracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, and Sanofi; has received honoraria from Celgene, Bristol Myers Squibb, Bayer, Amgen, Johnson & Johnson, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, AduroBiotech, Sanofi, and OncoTracker; and is a member on the Board of Directors or advisory committee of Antengene.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The authors obtained permission from Komodo and from Loopback Analytics to access and use the databases under license for this study. The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act, specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}